secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0000950170-23-041597
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics Q2 net loss $12.2M; REASSURE trial 50% enrolled, topline data expected Q2 2024
--------------------------------------------------------------------------------

- Net loss $12.2M in Q2 2023 vs $6.7M in Q2 2022; non-GAAP net loss $10.0M.
- R&D expense $9.0M (up from $4.0M) driven by REASSURE trial costs; G&A $1.9M (down from $4.1M).
- Cash and short-term investments $44.7M; cash runway into Q3 2024.
- REASSURE trial: 50% enrollment (target 1,966 patients); enrollment completion expected Q1 2024, topline data Q2 2024.
- New Japanese patent for oral sulopenem bilayer tablet granted; expires no earlier than 2039.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023041597/0000950170-23-041597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023041597/itrm-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer